ArticlePloS one2026
Identification of AC025811.3 and AC012354.6 as two critical survival-related lncRNAs for uterine corpus cancer.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uterine corpus endometrial carcinoma (UCEC) ranks as the most frequently diagnosed gynecologic malignancy and the second leading cause of gynecologic cancer-related mortality. Long non-coding RNAs (lncRNAs) have emerged as critical regulators of gene expression and tumor biology; however, their prognostic significance in UCEC remains largely unexplored. To systematically identify survival-associated lncRNA biomarkers, we integrated clinical and transcriptomic data from two independent cohorts: TCGA-UCEC (548 tumor, 35 normal) and CPTAC-Uterus (102 tumor, 15 normal). Following upper quartile normalization and ComBat-based batch effect correction, differentially expressed lncRNAs (FDR < 0.01, |log2FC| > 2) were identified using Student's t-test. The intersecting set of consistently dysregulated lncRNAs from both cohorts was subjected to Cox proportional hazards regression to identify survival-associated candidates. Functional inference was performed through Spearman correlation with protein-coding genes and Gene Set Enrichment Analysis (GSEA) of KEGG pathways. A total of 550 lncRNAs were consistently downregulated and 148 were upregulated in UCEC across both cohorts. Cox regression identified 30 survival-associated lncRNAs (FDR < 0.01), all with elevated expression correlating with worse overall survival. The top two candidates, AC025811.3 and AC012354.6, showed significant stage-dependent expression patterns across FIGO stages I-IV and were functionally enriched in immune regulation and carbohydrate metabolism pathways. In conclusions, AC025811.3 and AC012354.6 represent novel candidate prognostic lncRNA biomarkers in UCEC. Experimental validation, including FISH-based tissue localization and staged quantification, and functional assays, is warranted to confirm their biological roles.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.